{"id":"e1f93c2cafe0","type":"article","url":"https://hartvaat.nl/2025/12/24/infectiepreventie-bij-nieuwe-complementremmers-ingekapselde-micro-organismen/","title":"Infectiepreventie bij nieuwe complementremmers: ingekapselde micro-organismen","title_en":"Modern challenges in infection prevention: encapsulated organisms in the era of novel complement inhibitors","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","internist"],"tags":["complementremmers","iga-nefropathie"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)01024-5/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)01024-5/fulltext","authors":["Ayman Al Jurdi","Camille N. Kotton","Richard Lafayette"],"significance":5,"published":"2025-12-24","source_date":"2025-12-24","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/contrastmiddel-en-nierfunctie/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This review addresses infection prevention strategies for patients receiving novel complement inhibitors approved for aHUS, IgA nephropathy, and C3 glomerulopathy. The risk of encapsulated organism infections requires systematic vaccination and monitoring protocols.","created":"2026-07-03T10:25:39Z","updated":"2026-07-03T13:25:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Complementremmers zijn goedgekeurd voor aHUS, IgA-nefropathie en C3-glomerulopathie. Deze review bespreekt het infectierisico door ingekapselde organismen bij gebruik van nieuwe complementremmers en strategieën voor preventie.","abstract_original":"Complement inhibitors are now approved for use in atypical hemolytic uremic syndrome, IgA nephropathy, and C3 glomerulopathy. They are being studied widely in kidney disease, and more indications may soon arise. This review addresses an approach to preventing infectious complications, particularly encapsulated organism infections, and will hopefully serve as guidance for nephrologists utilizing these agents."}